About
Picodya introduces game-changing technology with the proven potential to empower diagnostics access worldwide.
Picodya's B-Matrix, microfluidic lab-on-a-chip platform redefines diagnostics, supports simultaneous hybrid testing for both molecular and immunoassays with multiplexed syndromic panels for various sample types. Its innovative multi-use consumables utilization allows for massive cost reduction while the minimal sample volume offers less invasive patients’ experience. The system unique and modular design supports diverse clinical settings anywhere from a large hospital systems’ laboratory through urgent care settings and physician offices as well as emerging settings such as airports, pharmacies and patients’ homes.
Funding history · 4 rounds · $51.4M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Picodya Technologies founded?
- Picodya Technologies was founded in February 2018.
- What is Picodya Technologies' primary product?
- Picodya Technologies' primary product is the B-Matrix, a microfluidic lab-on-a-chip platform for In Vitro Diagnostics (IVD).
- What was Picodya Technologies' most recent funding round?
- Picodya Technologies completed a SAFE funding round in November 2023, raising $7,500,000. For full financing history, please refer to startupim.
- What is the total amount of funding Picodya Technologies has raised to date?
- Picodya Technologies has raised a total of $51,400,000 USD across all funding rounds.
- How many employees does Picodya Technologies currently have?
- Picodya Technologies currently has 31 employees.
- Which organization adopted Picodya's diagnostics system in January 2024?
- In January 2024, Picodya's diagnostics system was adopted through a NIH pandemic initiative, according to a report by medicaldevice-network.com.
- Which Israeli government agency has provided grants to Picodya Technologies?
- The Israel Innovation Authority (IIA) has provided multiple grants to Picodya Technologies, with the most recent one in January 2024 for $300,000.
- What is the core functionality of Picodya's B-Matrix platform?
- Picodya's B-Matrix platform supports simultaneous hybrid testing for both molecular and immunoassays with multiplexed syndromic panels for various sample types.
- Who are the founders of Picodya Technologies?
- The founders of Picodya Technologies include Eli Ben Simon, Tzvika Barkai, and Yehuda Yavets-Chen.